bpc 157 for chronic pain FDA panel votes to place popular peptide BPC-157 on compounding list bpc 157 fda status 2025

First isolated from human gastric juice in 1993 by Croatian researchers, this 15-amino acid peptide demonstrates remarkable tissue-protective properties across multiple organ systems

It carries a fatty acid chain that promotes albumin binding, extending its half-life to approximately seven days and enabling once-weekly dosing

Protocol: Oral BPC-157 capsules are preferred over injectable for this stack because the target is the gastrointestinal lining

We stand by our peptide quality with an industry-leading 90-day return policy and a guarantee that our peptides meet or exceed 99% purity

The brand has built a reputation around reliability, and the BPC-157 capsule range fits that profile with clean formulation, accurate measurements and professional packaging